To be the gold-standard partner to drug developers, bridging the translational gap with the most human-relevant evidence
Preclinical drug development has long relied on proxy models that do not accurately represent human disease, creating a costly translational gap where promising therapies fail in human trials.
We exist to close that gap and to ensure the best science becomes the best medicine.
By enabling studies in human tissue cultured with our proprietary bioreactor technology, we create a more definitive basis for understanding how therapies will perform in real human disease.
As your strategic scientific partner, we translate complex biology into confident clinical strategy through a fundamentally different standard of preclinical testing.
The most human-relevant evidence
Our proprietary bioreactor technology maintains the native 3D cellular architecture and functional signaling pathways in viable human tissue, enabling extended study duration without the loss of cellular diversity and tissue integrity.
An uncompromising, decision-grade data system
We translate raw, high-fidelity biological insight into a scalable and highly reproducible evidentiary platform. Governed by strict ISO 9001 standards, our purpose-built workflows ensure every data point we deliver is robust and actionable.
Expert-led, consultative study design
We are far more than a standard testing facility. Driven by internationally recognized experts with over a century of collective expertise, we support you by creating the optimal studies tailored precisely to the specific mechanistic nuances of your high-potential asset.
We fulfill our mission by helping you fulfill yours
From new studies to established programs that need definitive human validation, we are here to support what comes next.
Led by recognized experts
Our executive leadership brings internationally recognized expertise across disease biology, translational science and human tissue research. FibroFind was founded by Professors Jelena Mann, Derek Mann, Fiona Oakley and Dr. Lee Borthwick, whose work established the scientific foundations of the business.
Today, our wider leadership team carries that expertise forward, combining academic, clinical and commercial insight to support global biopharma sponsors and turn complex scientific understanding into decision-grade pipeline strategy.
The evidence your program demands
Speak to our team about your programme.